BACKGROUND: Gingerols and shogaols are the main active constituents in var. Valeton has been reported for its anti-anxiety activity. Anti-anxiety drugs, such as benzodiazepines, alleviate anxiety disorders by enhancing the activity of gamma-aminobutyric acid type A (GABA) receptors through positive allosteric regulation at the α1/γ2 interface extracellular domain. PURPOSE: To elucidate the binding energy and stability of gingerols and shogaols toward human GABA receptor (hGABAR), compared to their known allosteric agonist (diazepam), and further phytochemical analysis in the ethanol extract of var. Valeton rhizome (EEZO). METHODS: The ligands, namely gingerols (6-, 8-, and 10-gingerol) and shogaols (6-, 8-, and 10-shogaol), were evaluated by pre-ADMET screening tools and molecular docking simulation towards hGABAR α1/γ2 subtype (PDB ID: 6X3X). Compounds with the best pre-ADMET profile and affinity were subjected to a 200 ns molecular dynamics (MD) simulation. The UPLC analysis was performed to detect and quantify gingerol and shogaol in EEZO. RESULTS: The best pre-ADMET prediction was shown by 6-gingerol, whereas the molecular docking simulations revealed that the best binding affinity and stability were shown by 6-gingerol (-7.41 kcal/mol) and 10-shogaol (-8.24 kcal/mol), which are comparable to that of diazepam. They build hydrogen bonds with α1 Ser206 and pi interaction with γ2 Phe77. The MD simulation confirmed that the stability of the 10-shogaol/hGABAR and 6-gingerol/hGABAR complexes is equal to that of diazepam/hGABAR. The UPLC analysis resulted in a level of 44.98 µg/mL for 6-gingerol and 2.52 µg/mL for 10-shogaol. CONCLUSION: 6-Gingerol and 10-shogaol of EEZO may have the potential to be developed as novel allosteric agonists of human GABA receptors, thus explaining their anti-anxiety activity. However, the activity towards the human GABA receptor is lower than diazepam, its known allosteric agonist.